Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Unknown 1Enrolling by invitation 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 110Thoracic 6Head & Neck 3Breast 2Tumor-Agnostic 1Other solid neoplasm 1

Conditions

HER2-positive 1

Interventions

Injections 17Cisplatin 15Carboplatin 15Oxaliplatin 11Gemcitabine 11pembrolizumab 8Capecitabine 8toripalimab 7Paclitaxel 7Etoposide 7Cyclophosphamide 7Pemetrexed 6Irinotecan 6Drug Therapy 6spartalizumab 5fludarabine 5camrelizumab 5Vincristine 5Radiotherapy 5Leucovorin 5tislelizumab 4apatinib 4anlotinib 4Interleukin-2 4Immune Checkpoint Inhibitors 4Granulocyte-Macrophage Colony-Stimulating Factor 4Fluorouracil 4Docetaxel 4Bevacizumab 4tremelimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × S 1 (combination) × Other solid neoplasm × Clear all
NCT05218148 2022-04-06

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

ChineseAMS

Phase 2 Unknown
44 enrolled
GastrointestinalOther solid neoplasm

HER2-positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡